Resistance to antifolates

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.

Original languageEnglish (US)
Pages (from-to)7431-7457
Number of pages27
JournalOncogene
Volume22
Issue number47 REV. ISS. 6
DOIs
StatePublished - Oct 20 2003

Fingerprint

Folic Acid Antagonists
Polyglutamic Acid
Antimetabolites
Cytotoxins
Bone Marrow Transplantation
Drug Resistance
Methotrexate
Bone Marrow Cells
Pharmaceutical Preparations
Genetic Therapy
Antineoplastic Agents
Action Potentials
Hydrolysis
Stem Cells
Pharmacology
Mutation
Enzymes

Keywords

  • Antifolates
  • BCRP
  • Dihydrofolate reductase
  • Exporters
  • Folate receptors
  • Folates
  • Folic acid
  • Folylpolyglutamate synthetase
  • GAR transforylase
  • Leucovorin
  • Methotrexate
  • MRP
  • PGP
  • Polyglutamate
  • Raltitrexed reduced folate carrier
  • Thymidylate synthase

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Resistance to antifolates. / Zhao, Rongbao; Goldman, I. David.

In: Oncogene, Vol. 22, No. 47 REV. ISS. 6, 20.10.2003, p. 7431-7457.

Research output: Contribution to journalArticle

Zhao, Rongbao ; Goldman, I. David. / Resistance to antifolates. In: Oncogene. 2003 ; Vol. 22, No. 47 REV. ISS. 6. pp. 7431-7457.
@article{b11d04c7d5b548a9b4039b20772ae6ef,
title = "Resistance to antifolates",
abstract = "The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.",
keywords = "Antifolates, BCRP, Dihydrofolate reductase, Exporters, Folate receptors, Folates, Folic acid, Folylpolyglutamate synthetase, GAR transforylase, Leucovorin, Methotrexate, MRP, PGP, Polyglutamate, Raltitrexed reduced folate carrier, Thymidylate synthase",
author = "Rongbao Zhao and Goldman, {I. David}",
year = "2003",
month = "10",
day = "20",
doi = "10.1038/sj.onc.1206946",
language = "English (US)",
volume = "22",
pages = "7431--7457",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "47 REV. ISS. 6",

}

TY - JOUR

T1 - Resistance to antifolates

AU - Zhao, Rongbao

AU - Goldman, I. David

PY - 2003/10/20

Y1 - 2003/10/20

N2 - The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.

AB - The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.

KW - Antifolates

KW - BCRP

KW - Dihydrofolate reductase

KW - Exporters

KW - Folate receptors

KW - Folates

KW - Folic acid

KW - Folylpolyglutamate synthetase

KW - GAR transforylase

KW - Leucovorin

KW - Methotrexate

KW - MRP

KW - PGP

KW - Polyglutamate

KW - Raltitrexed reduced folate carrier

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=0344393780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344393780&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206946

DO - 10.1038/sj.onc.1206946

M3 - Article

VL - 22

SP - 7431

EP - 7457

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 47 REV. ISS. 6

ER -